An interventional study of Educational intervention for doctors and nurses in Hypertension, sponsored by Region Stockholm. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Region Stockholm · Not applicable, Interventional, and Treatment
The aim is to investigate whether information and educational initiatives on the Swedish national care pathway for hypertension, directed at primary care centers, lead to an increase in the proportion of patients achieving target blood pressure.
Intervention: Information and educational initiatives on the national care pathway for hypertension, including specific recommendations regarding treatment and the use of digital support tools Study sites: Publicly funded primary care centers within Stockholm Region (SLSO) Study period: Primary analysis covering 2025-2028. Data extraction covering the period 2020-2028 Design: Stepped-wedge cluster-randomized trial Number of study units: Sixteen primary care centers will receive the intervention every 6 months during the period January 2027 to December 2028, for a total of 64 primary care centers.
Condition: Hypertension
Inclusion criteria: Publicly funded primary care centers within Stockholm Region (SLSO)
Exclusion criteria: Not applicable
Control group: Primary care centers that have not yet received the intervention serve as controls until they receive the intervention.
Definition of hypertension: Listed patients 18 years or above with a diagnosis of hypertension (ICD-10 I10-I15) during the last five years
Pre-defined subgroup analyses: Sex and age group (18-79, 80+ years)
6,114 studies on the registry are indexed under Hypertension; 912 are open to participants now.
This study's planned enrollment of 120,000 is above the median of 100 across 4,575 interventional studies indexed under Hypertension.
Browse Hypertension studies →Region Stockholm is the lead sponsor of 121 studies on the registry; 69 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Publicly funded primary care centers within Stockholm Region (SLSO)
Exclusion Criteria:
Not applicable
Educational intervention for doctors and nurses.
Other: Educational intervention for doctors and nurses
Control arm where each primary care unit is considered a control prior to the intervention
Educational intervention for doctors and nurses. Information and educational initiatives on the national care pathway for hypertension, including specific recommendations regarding treatment and the use of digital support tools. The intervention consists of in-person lectures by a physician educator, combined with an information package for physicians, nurses and patients. This includes standardised treatment algorithms with early combination therapy. Educational material will be made available electronically. Primary care centers will be provided with tools for continuous monitoring of their performance.
Change from baseline in the proportion of patients with blood pressure <130/<80 mmHg
Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals whose last recorded blood pressure was below the target according to the person-centered and integrated care pathway (PSVF) for hypertension (\<130/\<80 mmHg), irrespective of measurement method (office, home, or ambulatory blood pressure monitoring). The outcome is assessed in each 6-month interval, and the primary effect measure is the average effect over the first 12 months after each center's scheduled crossover.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in the proportion of patients with their blood pressure measured
Proportion of patients with a diagnosis of hypertension who, in each 6-month interval had their blood pressure measured
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in the proportion of patients who were dispensed statin therapy
Proportion of patients with a diagnosis of hypertension who were dispensed statin therapy
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in the proportion of patients who achieved an office blood pressure <140/<90 mmHg, a home blood pressure <135/<85 mmHg, or an ambulatory blood pressure <135/<85 mmHg
Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals who achieved an office blood pressure \<140/\<90 mmHg, a home blood pressure \<135/\<85 mmHg, or an ambulatory blood pressure \<135/\<85 mmHg. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in the proportion of patients who were dispensed combination therapy with antihypertensive agents
Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more)
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in the proportion of patients who achieved LDL cholesterol targets according to the ESC guidelines
Proportion of patients with a diagnosis of hypertension and at least one blood pressure recorded in the 6-month interval who achieved LDL cholesterol targets according to the ESC guidelines (among patients with LDL cholesterol measured). Very high risk \<1.4 mmol/L; high risk \<1.8 mmol/L, moderate risk \<2.6 mmol/L).
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Observed population trajectory of the proportion of patients with hypertension below 130/80 mmHg
Observed population trajectory describing the proportion of patients with hypertension below the PSVF target 130/80 mmHg per half-year from H1-2025 to H2-2028, using the last blood pressure in that half-year. If no measurement is recorded, the most recent value during the last 12 months is carried forward. Missing values will be regarded as not treated to target. This is a descriptive series with no model terms and no p-values. It shows the total change in the population, combining the secular trend and the rollout.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change from baseline in proportion of patients with uncontrolled blood pressure that received treatment intensification
Proportion of patients with a diagnosis of hypertension and a last blood pressure \>= 130/80 mmHg in the 6-month interval who were dispensed combination therapy with antihypertensive agents (2, 3, or more)
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Change in last measured systolic BP in mmHg per patient period
Mean systolic blood pressure in patients with a diagnosis of hypertension and at least one blood pressure recorded in 6-month intervals. The outcome is assessed in each 6-month interval, and the effect measure is the average effect over the first 12 months after each center's scheduled crossover.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Mean number of primary care contacts per patient
Resource utilization. Mean number of primary care contacts per patient per 6-month interval, by staff category, in total and with a hypertension diagnosis registered at the visit. Reported descriptively per sequence and period.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Mean number of laboratory tests per patient
Resource utilization. Mean number of laboratory tests (creatinine, potassium, sodium, lipids) per patient per 6-month interval. Reported separately for each test type. Reported descriptively per sequence and period.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Mean number of blood pressure measurements per patient
Resource utilization. Mean number of blood pressure measurements per patient per 6-month interval, by measurement type. Reported by measurement type (office, home, ambulatory). Reported descriptively per sequence and period.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Mean dispensed defined daily doses (DDDs) per patient
Resource utilization. Mean dispensed defined daily doses (DDDs) of antihypertensives and statins per patient per 6-month interval. Reported separately for antihypertensive agents and statins. Reported descriptively per sequence and period.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Mean pharmacy cost per patient
Resource utilization. Mean pharmacy cost of dispensed antihypertensives and statins per patient per 6-month interval. Reported separately for antihypertensive agents and statins. Reported descriptively per sequence and period.
Time frame: 6-month intervals consisting of 2 control periods, 1 baseline period and 4 intervention periods
Adverse drug reactions related to antihypertensive medication
Safety outcome. Adverse drug reactions related to antihypertensive medication: acute kidney injury, hypotension or syncope, orthostatic hypotension, and fall injury. Based on hospitalizations with relevant ICD-10 codes.
Time frame: First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover
Myocardial infarction and stroke
Hypertension-related complications: myocardial infarction and stroke
Time frame: First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover
All-cause mortality
All-cause mortality
Time frame: First event per patient and 6-month interval, analyzed as event rates per person-time and reported as a rate ratio averaged over the first 12 months after crossover
No study locations are listed for this record.
Plan to share: No
Start is estimated for Jan 2027; primary completion for Dec 2028, 23 months later.
Of 1,403 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 23 months is close to that.
Counting every sponsor, half of 1,498 studies reached it within 23 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.